EBioMedicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=422, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206789, encodeId=a9fa1206e8984, content=请问各位前辈这个杂志一般几天送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cbb2338538, createdName=122863d1m37(暂无昵称), createdTime=Tue Mar 29 07:52:55 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588301, encodeId=671658830116, content=你好，我想请问一下，投稿里面有个剽窃检查plagiarism check 怎么填啊，好像是必填的，是要填自己的查重结果么？珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, beContent=珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffdc5315297, createdName=洪诗福, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津)]

2021-08-23 惨兮兮的RA

审稿速度:2.0 | 投稿命中率:25.0
经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。

131 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=422, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206789, encodeId=a9fa1206e8984, content=请问各位前辈这个杂志一般几天送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cbb2338538, createdName=122863d1m37(暂无昵称), createdTime=Tue Mar 29 07:52:55 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588301, encodeId=671658830116, content=你好，我想请问一下，投稿里面有个剽窃检查plagiarism check 怎么填啊，好像是必填的，是要填自己的查重结果么？珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, beContent=珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffdc5315297, createdName=洪诗福, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津)]

2019-11-05 Leoharlan

审稿速度:3.0 | 投稿命中率:25.0
经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。
编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！
之后有问题的朋友可以交流

382 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=422, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206789, encodeId=a9fa1206e8984, content=请问各位前辈这个杂志一般几天送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cbb2338538, createdName=122863d1m37(暂无昵称), createdTime=Tue Mar 29 07:52:55 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588301, encodeId=671658830116, content=你好，我想请问一下，投稿里面有个剽窃检查plagiarism check 怎么填啊，好像是必填的，是要填自己的查重结果么？珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, beContent=珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffdc5315297, createdName=洪诗福, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津)]

2021-09-09 ms3211462863917894

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：转化医学;药理学
经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。

94 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=422, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206789, encodeId=a9fa1206e8984, content=请问各位前辈这个杂志一般几天送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cbb2338538, createdName=122863d1m37(暂无昵称), createdTime=Tue Mar 29 07:52:55 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588301, encodeId=671658830116, content=你好，我想请问一下，投稿里面有个剽窃检查plagiarism check 怎么填啊，好像是必填的，是要填自己的查重结果么？珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, beContent=珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffdc5315297, createdName=洪诗福, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津)]

2022-01-30 1de49043m36(暂无匿称)

刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命

422 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=422, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206789, encodeId=a9fa1206e8984, content=请问各位前辈这个杂志一般几天送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cbb2338538, createdName=122863d1m37(暂无昵称), createdTime=Tue Mar 29 07:52:55 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588301, encodeId=671658830116, content=你好，我想请问一下，投稿里面有个剽窃检查plagiarism check 怎么填啊，好像是必填的，是要填自己的查重结果么？珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, beContent=珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffdc5315297, createdName=洪诗福, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津)]

2022-10-20 y-y-y

审稿速度:2.0
偏重的研究方向：转化医学;临床转化
经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。

133 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=422, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206789, encodeId=a9fa1206e8984, content=请问各位前辈这个杂志一般几天送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cbb2338538, createdName=122863d1m37(暂无昵称), createdTime=Tue Mar 29 07:52:55 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588301, encodeId=671658830116, content=你好，我想请问一下，投稿里面有个剽窃检查plagiarism check 怎么填啊，好像是必填的，是要填自己的查重结果么？珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, beContent=珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffdc5315297, createdName=洪诗福, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津)]

2020-09-24 亚*拉

审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0
偏重的研究方向：精神病学
经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。

170 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=422, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206789, encodeId=a9fa1206e8984, content=请问各位前辈这个杂志一般几天送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cbb2338538, createdName=122863d1m37(暂无昵称), createdTime=Tue Mar 29 07:52:55 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588301, encodeId=671658830116, content=你好，我想请问一下，投稿里面有个剽窃检查plagiarism check 怎么填啊，好像是必填的，是要填自己的查重结果么？珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, beContent=珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffdc5315297, createdName=洪诗福, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津)]

2022-11-22 guolihuihelan_91618321

这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利

171 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=422, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206789, encodeId=a9fa1206e8984, content=请问各位前辈这个杂志一般几天送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cbb2338538, createdName=122863d1m37(暂无昵称), createdTime=Tue Mar 29 07:52:55 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588301, encodeId=671658830116, content=你好，我想请问一下，投稿里面有个剽窃检查plagiarism check 怎么填啊，好像是必填的，是要填自己的查重结果么？珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, beContent=珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffdc5315297, createdName=洪诗福, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津)]

2022-03-29 122863d1m37(暂无昵称)

请问各位前辈这个杂志一般几天送审啊

340 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=422, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206789, encodeId=a9fa1206e8984, content=请问各位前辈这个杂志一般几天送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cbb2338538, createdName=122863d1m37(暂无昵称), createdTime=Tue Mar 29 07:52:55 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588301, encodeId=671658830116, content=你好，我想请问一下，投稿里面有个剽窃检查plagiarism check 怎么填啊，好像是必填的，是要填自己的查重结果么？珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, beContent=珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffdc5315297, createdName=洪诗福, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津)]

2020-04-06 洪诗福

你好，我想请问一下，投稿里面有个剽窃检查plagiarism check 怎么填啊，好像是必填的，是要填自己的查重结果么？珑铭臻 2020-03-13 00:00:00 发表:
好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档

珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档

27 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1010684, encodeId=1c9b1010684ce, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2021.08.19投出一篇文章 2021.08.23送审如果有后续，我会及时更新。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230530/9e9e59acc0944ac59084af44dd4cbd04/63a72e5f377a433f8eaa02d3b314c533.jpg, createdBy=de935401089, createdName=惨兮兮的RA, createdTime=Mon Aug 23 18:37:15 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579399, encodeId=c2085e9399dc, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：6.22投的搞，7天后就审完了，给2个月的时间大修，9.29号返修回去，又审了一个月，本来想催一下，因为这个杂志平时审稿都挺快的。那不知到了整整一个月的时候说基本快接受了，还改一下p值和统计学，当天返回去第二天就接受了。历时4个月，主要是自己返修了2月，总体是很快的。 编辑推荐参选封面文章，现在正在找公司画图，希望能做封面！！！ 之后有问题的朋友可以交流, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqrktn59XpSJFcx3ZZRaiayeeUqgtmibRhUqqH8MXHtW3a1mt6AOeBqYrGFN0Vib60wvhAD5fcyiaxVLg/132, createdBy=b6b21645984, createdName=Leoharlan, createdTime=Tue Nov 05 20:57:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015953, encodeId=53371015953ac, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：转化医学;药理学 经验分享：最近中了一篇，分享下投稿经验 6月初投出去，编辑很快就处理了稿件，当周就送审了。一共三个审稿人，三个星期后意见返回建议小修。两星期后修回，又多了第四个审稿人意见。总共来回修改四次才最终接收。该杂志官方公布的接收率为13%，并且逐年降低，能投的尽快投吧，明年就上10了，预计11-12左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/N3zKgaH6SrlOOMykibO4Il0icPd35wXHdrf49xjPOCWOUPGKadZzSTEbOIazZaj2pI1EQkWunJaPTzjWn0gxUxEQ/132, createdBy=7d145136054, createdName=ms3211462863917894, createdTime=Thu Sep 09 08:36:29 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189243, encodeId=8be9118924378, content=刚投了一篇，投稿系统整的太复杂了，要一个twitter账号，去哪也下不了下来，真要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=422, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe1e1686453, createdName=1de49043m36(暂无匿称), createdTime=Sun Jan 30 00:51:13 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095030, encodeId=5ccb209503005, content=审稿速度:2.0 偏重的研究方向：转化医学;临床转化 经验分享：时隔三年有幸再中ebio，过程还算顺利，编辑一如既往的nice，祝愿期刊越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/23/389dc48415662ee39e08e2a072edca25.jpg, createdBy=7a8b2236930, createdName=y-y-y, createdTime=Thu Oct 20 20:19:31 CST 2022, time=2022-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888008, encodeId=a9cd888008ae, content=审稿速度:2.0 | 投稿命中率:25.0 | 版面费用:3500.0 偏重的研究方向：精神病学 经验分享：投的是一篇临床干预性研究。审稿人很专业，提了很多问题。共修稿两次，最终顺利接收。相比其他杂志而言，这个杂志对临床实施过程中的细节很关注，具体的protocol也需要同时投稿或发表在别处。预计分数会稳住。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/86b3a7c972534590b86fcfff881ac69e/8de5a3270f164d309ffaa1307cb049cc.jpg, createdBy=b0b62173620, createdName=亚*拉, createdTime=Thu Sep 24 16:52:53 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101887, encodeId=6fac210188ea4, content=这个杂志今年2022一月份成了柳叶刀子刊了，现在跟正苗红了，以后估计会越来越难，感觉得文章质量从今年开始也比以前有了提高，希望一切顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45fa2432519, createdName=guolihuihelan_91618321, createdTime=Tue Nov 22 07:32:45 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206789, encodeId=a9fa1206e8984, content=请问各位前辈这个杂志一般几天送审啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2cbb2338538, createdName=122863d1m37(暂无昵称), createdTime=Tue Mar 29 07:52:55 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588301, encodeId=671658830116, content=你好，我想请问一下，投稿里面有个剽窃检查plagiarism check 怎么填啊，好像是必填的，是要填自己的查重结果么？珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, beContent=珑铭臻 2020-03-13 00:00:00 发表: 好像没有您说的这么复杂，我只是提交了一份电子签名的PDF文档, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffdc5315297, createdName=洪诗福, createdTime=Mon Apr 06 00:00:00 CST 2020, time=2020-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174266, encodeId=54a121e426610, content=各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Mon Dec 11 14:28:48 CST 2023, time=2023-12-11, status=1, ipAttribution=天津)]

2023-12-11 ms1000000959787142 来自天津

各位大佬们，我想问一下这个杂志，Required Reviews Completed这一步大概多久呀，快一个月了，没变化呢

19 5

展开5条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务